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TriBiotica has combined molecular biology of cancer
and proprietary chemistry to implement an innovative
therapeutic approach to cancer treatment. Instead of
developing immunological reagents (such as cells, anti-
bodies or chimeric receptors) targeting antigens already
present on tumor cells, the new technology produces
novel structures that are not native to the tumor cell.
The generation of novel molecules in a tumor-specific
manner accordingly allows implementation of immu-
notherapeutic interventions that recognize and destroy
tumor cells. Unlike immunotherapy protocols that are
limited by availability of target antigens, TriBiotica’s
technology utilizes the tumor’s unique transcriptome to
force tumor cells to produce novel molecules that are
either toxic by themselves, or allow immunotherapeutic
destruction of the tumor cells without inducing toxicity
against normal cells. As a proof of concept, we have
used an HPV16 template from a cervical carcinoma cell
to create a FLAG-tag that is uniquely assembled in
HPV16 expressing tumor cells. Of the cervical cancer cell
lines Caski, HeLa, and C33A, only Caski contains the
HPV16 E6/E7 oncogene. Each of these lines was treated
with templated assembly of bio-orthogonal compounds
designed to produce FLAG tag peptide specifically in the
presence of HPV16 E6/E7 mRNA. At 24 hours post-
treatment, in situ production of FLAG tag in each tumor
type was assayed by ELISA. The results demonstrate that
FLAG tag is selectively produced in Caski cells harboring
the target HPV16 template. To our knowledge, this
represents the first oncogene-templated synthesis of a
peptide tag within living cells. The approach offers the
potential for producing a wide variety of biologically-
active molecules specifically in targeted cells, leaving nor-
mal cells unaffected. This technology offers a platform
that links next-generation sequencing technologies to
identify genetic markers of cancers as potential targets in
a vast array of tumors. Combined with genetic analyses,
the therapy is adaptable to the ever-changing genetic
landscape of tumors, as the same novel effector molecule
can be assembled on an almost limitless array of target
nucleic acid templates, so that it is possible to adapt the
formation of the novel therapeutic product molecule to
any target genetic templates arising from the outgrowth
subsets of tumor cells. Combined with appropriate diagnos-
tic testing, the TriBiotica technology has the potential to
create a new paradigm for targeting of tumor cells that
opens the door to the treatment of virtually any tumor type.
The technology relies on identifying specific tumor genetic
templates, and utilizing a proprietary technology that
assembles novel epitopes present only in the tumor cells.
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